SALT LAKE CITY—Sera Prognostics, Inc. (NASDAQ:SERA) Chief Financial Officer Austin Aerts recently sold shares of the company's Class A common stock, according to a recent filing with the Securities and Exchange Commission. The company, currently valued at $216 million, has seen its stock decline over 23% in the past week, according to InvestingPro data.
The transaction, which took place on January 10, 2025, involved the sale of 2,431 shares at a weighted average price of $8.06, generating a total of $19,593. The shares were sold in multiple transactions at prices ranging from $7.99 to $8.13. Since the sale, the stock has fallen to $6.37, though InvestingPro analysis indicates the company maintains a strong cash position, with liquid assets exceeding short-term obligations.
Following this sale, Aerts retains direct ownership of 283,325 shares of Sera Prognostics. The transaction was executed under a Rule 10b5-1 trading plan that Aerts adopted on May 22, 2024, allowing for prearranged stock transactions. InvestingPro's comprehensive analysis, including Fair Value estimates and 8 additional key insights, is available in the Pro Research Report.
In other recent news, Sera Prognostics disclosed in an SEC filing that the Society for Maternal Fetal Medicine (SMFM) has published an abstract with topline results from the PRIME study. The study, focusing on improving neonatal outcomes through prematurity risk assessment combined with clinical interventions, is set to be presented in detail soon. Following the presentation, Sera Prognostics plans to host a conference call and live audio webcast for an in-depth discussion of the PRIME study's outcomes.
In the company's recent financials, there was a decrease in net revenue to $29,000 from $42,000. Operating expenses rose by 8% to $8.9 million, and the net loss increased by 10% to $7.9 million. Despite these numbers, Sera Prognostics maintains a strong cash reserve of $74.3 million, projected to sustain operations into 2027.
The company is putting a spotlight on its PreTRM test, aiming to enhance its adoption to tackle rising preterm birth rates in the U.S. CEO Evguenia Lindgardt underlined the significance of the forthcoming publication of the PRIME clinical study results, which are expected to play a crucial role in securing payer support and influencing clinical guidelines. These recent developments form the backbone of Sera Prognostics' strategy for commercial growth and maintaining solid cash reserves in the coming years.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.